Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 27

1.

The Beneficial Effects of Valproic Acid in Thyroid Cancer Are Mediated through Promoting Redifferentiation and Reducing Stemness Level: An In Vitro Study.

Haghpanah V, Malehmir M, Larijani B, Ahmadian S, Alimoghaddam K, Heshmat R, Ghavamzadeh A, Adabi K, Ghaffari SH.

J Thyroid Res. 2014;2014:218763. doi: 10.1155/2014/218763. Epub 2014 May 15.

2.

Sodium valproate-related hyperammonaemic encephalopathy.

Pegg EJ, Zaman F.

BMJ Case Rep. 2014 Apr 10;2014. pii: bcr2014203899. doi: 10.1136/bcr-2014-203899.

PMID:
24722719
3.

Valproic acid downregulates NF-κB p50 activity and IRAK-1 in a progressive thyroid carcinoma cell line.

Schwertheim S, Worm K, Schmid KW, Sheu-Grabellus SY.

Horm Metab Res. 2014 Mar;46(3):181-6. doi: 10.1055/s-0034-1367043. Epub 2014 Feb 13.

PMID:
24526373
4.

Repositioning therapy for thyroid cancer: new insights on established medications.

Kushchayeva Y, Jensen K, Burman KD, Vasko V.

Endocr Relat Cancer. 2014 May 6;21(3):R183-94. doi: 10.1530/ERC-13-0473. Print 2014 Jun. Review.

5.

Valproic acid sensitizes TRAIL-resistant anaplastic thyroid carcinoma cells to apoptotic cell death.

Cha HY, Lee BS, Kang S, Shin YS, Chang JW, Sung ES, Kim YS, Choi JW, Kim JH, Kim CH.

Ann Surg Oncol. 2013 Dec;20 Suppl 3:S716-24. doi: 10.1245/s10434-013-3232-y. Epub 2013 Aug 28.

PMID:
23982257
6.

Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.

Kurzrock R, Atkins J, Wheler J, Fu S, Naing A, Busaidy N, Hong D, Sherman S.

Ann Oncol. 2013 Sep;24(9):2256-61. doi: 10.1093/annonc/mdt177. Epub 2013 May 14.

7.

Cooperation of histone deacetylase inhibitors SAHA and valproic acid in promoting sodium/iodide symporter expression and function in rat Leydig testicular carcinoma cells.

Maggisano V, Puppin C, Celano M, D'Agostino M, Sponziello M, Micali S, Navarra M, Damante G, Filetti S, Russo D.

Endocrine. 2014 Feb;45(1):148-52. doi: 10.1007/s12020-013-9972-4. Epub 2013 May 1.

PMID:
23636804
8.

Valproic acid reduces the tolerability of temsirolimus in children and adolescents with solid tumors.

Coulter DW, Walko C, Patel J, Moats-Staats BM, McFadden A, Smith SV, Khan WA, Bridges AS, Deal AM, Oesterheld J, Davis IJ, Blatt J.

Anticancer Drugs. 2013 Apr;24(4):415-21. doi: 10.1097/CAD.0b013e32835dc7c5.

9.

Sodium/iodide symporter is expressed in the majority of seminomas and embryonal testicular carcinomas.

Micali S, Maggisano V, Cesinaro A, Celano M, Territo A, Reggiani Bonetti L, Sponziello M, Migaldi M, Navarra M, Bianchi G, Filetti S, Russo D.

J Endocrinol. 2013 Jan 18;216(2):125-33. doi: 10.1530/JOE-12-0495. Print 2013 Feb. Review.

10.

Expression and biologic significance of adiponectin receptors in papillary thyroid carcinoma.

Cheng SP, Liu CL, Hsu YC, Chang YC, Huang SY, Lee JJ.

Cell Biochem Biophys. 2013 Mar;65(2):203-10. doi: 10.1007/s12013-012-9419-1.

PMID:
22907586
11.

The expression of translocator protein in human thyroid cancer and its role in the response of thyroid cancer cells to oxidative stress.

Klubo-Gwiezdzinska J, Jensen K, Bauer A, Patel A, Costello J Jr, Burman KD, Wartofsky L, Hardwick MJ, Vasko VV.

J Endocrinol. 2012 Aug;214(2):207-16. doi: 10.1530/JOE-12-0081. Epub 2012 May 29.

12.

Novel molecular targeted therapies for refractory thyroid cancer.

Perez CA, Santos ES, Arango BA, Raez LE, Cohen EE.

Head Neck. 2012 May;34(5):736-45. doi: 10.1002/hed.21755. Epub 2011 May 4. Review.

PMID:
21544895
13.

Modulation of matrix metalloproteinase activity in human thyroid cancer cell lines using demethylating agents and histone deacetylase inhibitors.

Mitmaker EJ, Griff NJ, Grogan RH, Sarkar R, Kebebew E, Duh QY, Clark OH, Shen WT.

Surgery. 2011 Apr;149(4):504-11. doi: 10.1016/j.surg.2010.10.007. Epub 2010 Dec 30.

PMID:
21193210
14.

Downregulation of survivin and aurora A by histone deacetylase and RAS inhibitors: a new drug combination for cancer therapy.

Biran A, Brownstein M, Haklai R, Kloog Y.

Int J Cancer. 2011 Feb 1;128(3):691-701. doi: 10.1002/ijc.25367.

PMID:
20473860
15.

Novel treatment of medullary thyroid cancer.

Sugawara M, Geffner DL, Martinez D, Hershman JM.

Curr Opin Endocrinol Diabetes Obes. 2009 Oct;16(5):367-72. doi: 10.1097/MED.0b013e3283304f0c. Review.

PMID:
19633548
16.

Inhibition of growth in medullary thyroid cancer cells with histone deacetylase inhibitors and lithium chloride.

Adler JT, Hottinger DG, Kunnimalaiyaan M, Chen H.

J Surg Res. 2010 Apr;159(2):640-4. doi: 10.1016/j.jss.2008.08.004. Epub 2008 Sep 4.

17.
18.

Notch1 mediates growth suppression of papillary and follicular thyroid cancer cells by histone deacetylase inhibitors.

Xiao X, Ning L, Chen H.

Mol Cancer Ther. 2009 Feb;8(2):350-6. doi: 10.1158/1535-7163.MCT-08-0585. Epub 2009 Feb 3.

19.

Effects of the histone deacetylase inhibitor valproic acid on the sensitivity of anaplastic thyroid cancer cell lines to imatinib.

Catalano MG, Pugliese M, Poli R, Bosco O, Bertieri R, Fortunati N, Boccuzzi G.

Oncol Rep. 2009 Feb;21(2):515-21.

PMID:
19148530
20.

Induction of iodide uptake in transformed thyrocytes: a compound screening in cell lines.

Fröhlich E, Brossart P, Wahl R.

Eur J Nucl Med Mol Imaging. 2009 May;36(5):780-90. doi: 10.1007/s00259-008-1024-6. Epub 2008 Dec 24.

PMID:
19107477
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk